- Report
- February 2026
- 100 Pages
India, Global
From €4343EUR$4,799USD£3,709GBP
- Report
- January 2026
- 150 Pages
Global
From €5384EUR$5,950USD£4,599GBP
- Report
- June 2026
- 189 Pages
Global
From €3208EUR$3,545USD£2,740GBP
€3564EUR$3,939USD£3,045GBP
- Report
- February 2026
- 250 Pages
Global
From €4063EUR$4,490USD£3,471GBP
- Report
- July 2026
- 193 Pages
Global
From €5294EUR$5,850USD£4,522GBP
- Report
- February 2026
- 148 Pages
Global
From €3619EUR$3,999USD£3,091GBP
- Report
- April 2026
- 301 Pages
Global
From €2262EUR$2,500USD£1,932GBP
- Report
- November 2025
- 160 Pages
Global
From €2859EUR$3,160USD£2,443GBP
€3574EUR$3,950USD£3,053GBP
- Report
- July 2025
- 275 Pages
Global
From €4520EUR$4,995USD£3,861GBP
- Report
- December 2025
- 150 Pages
Global
From €4389EUR$4,850USD£3,749GBP
- Report
- April 2026
- 143 Pages
Europe
From €3619EUR$3,999USD£3,091GBP
- Report
- July 2026
- 2285 Pages
Global
From €1453EUR$1,662USD£1,199GBP
- Report
- January 2026
- 185 Pages
Global
From €3208EUR$3,545USD£2,740GBP
€3564EUR$3,939USD£3,045GBP
- Report
- January 2026
- 187 Pages
Global
From €3208EUR$3,545USD£2,740GBP
€3564EUR$3,939USD£3,045GBP
- Report
- August 2025
- 188 Pages
Global
From €3208EUR$3,545USD£2,740GBP
€3564EUR$3,939USD£3,045GBP
- Report
- February 2026
- 250 Pages
Global
From €4063EUR$4,490USD£3,471GBP
- Report
- February 2026
- 250 Pages
Global
From €4063EUR$4,490USD£3,471GBP
- Report
- February 2026
- 250 Pages
Global
From €4063EUR$4,490USD£3,471GBP
- Report
- May 2026
- 177 Pages
Global
From €4072EUR$4,500USD£3,478GBP
- Report
- July 2025
- 181 Pages
Global
From €4072EUR$4,500USD£3,478GBP

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more